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Abstract
Background: Tuberculosis (TB) and multidrug-resistance tuberculosis (MDR-TB) pose serious challenges to global
health, particularly in China, which has the second highest case burden in the world. Disparities in access to care
for the poorest, rural TB patients may be exacerbated for MDR-TB patients, although this has not been investigated
widely. We examine whether certain patient groups experience different barriers to accessing TB services, whether
there are added challenges for patients with MDR-TB, and how patients and health providers cope in Yunnan, a
mountainous province in China with a largely rural population and high TB burden.
Methods: Using a qualitative study design, we conducted five focus group discussions and 47 in-depth interviews
with purposively sampled TB and MDR-TB patients and healthcare providers in Mandarin, between August 2014
and May 2015. Field-notes and interview transcripts were analysed via a combination of open and thematic coding.
Results: Patients and healthcare providers consistently cited financial constraints as the most common barriers to
accessing care. Rural residents, farmers and ethnic minorities were the most vulnerable to these barriers, and patients
with MDR-TB reported a higher financial burden owing to the centralisation and longer duration of treatment. Support
in the form of free or subsidised treatment and medical insurance, was deemed essential but inadequate for alleviating
financial barriers to patients. Most patients coped by selling their assets or borrowing money from family members,
which often strained relationships. Notably, some healthcare providers themselves reported making financial and other
contributions to assist patients, but recognised these practices as unsustainable.
Conclusions: Financial constraints were identified by TB and MDR-TB patients and health care professionals as the
most pervasive barrier to care. Barriers appeared to be magnified for ethnic minorities and patients coming from rural
areas, especially those with MDR-TB. To reduce financial barriers and improve treatment outcomes, there is a need for
further research into the total costs of seeking and accessing TB and MDR-TB care. This will enable better assessment
and targeting of appropriate financial support for identified vulnerable groups and geographic development
of relevant services.
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Background
China has the second highest tuberculosis (TB) and
multidrug-resistant TB (MDR-TB) burden in the world
[1]. This is in spite of meeting its TB control targets, re-
ducing overall prevalence and achieving 100% popula-
tion coverage with free standardised TB services under
Directly Observed Therapy Short Course (DOTS) [2].
However, in practice, service coverage is not equally dis-
tributed, with a higher concentration of resources in
eastern China and urban areas [3]. Patients thus con-
tinue to face barriers to diagnosis, treatment and care,
resulting in long delays in access to services and inequities
in population burden of TB and accessing care [4–6]. The
most commonly cited barrier to the successful treatment
of both tuberculosis and multidrug-resistant tuberculosis
(TB/MDR-TB) is financial [5–11]. Studies indicate that
provision of free TB diagnosis and treatment mitigates
direct costs, but does not eliminate indirect out-of-
pocket patient costs [8, 12–16], which can be substan-
tial and may include extra diagnostic tests, hospitalisa-
tion fees and drugs for side-effects [11, 12, 17–20].
These issues are likely to be further exacerbated for
MDR-TB patients, due to the relatively high cost and
complexity of care relative to drug sensitive TB, and
those living rural areas [13, 21], who account for 70%
of TB patients in China [22–24]. The New Rural Coopera-
tive Medical Scheme (NRCMS) goes some way to alleviat-
ing the direct health-related costs for rural registered TB/
MDR-TB patients. However, it does not cover outpatients
costs, which often constitute the majority of expenses as-
sociated for TB/MDR-TB patients [25, 26]. Furthermore,
patients living in remote and rural areas have to travel fur-
ther and incur greater total costs for equivalent services,
or may receive health care from providers with less experi-
ence and knowledge of TB [3, 5].
Total indirect and direct treatment costs associated
with TB/MDR-TB care may equal or exceed a patient
and/or household’s income-often identified as cata-
strophic health costs. Thus, patients may have to rely on
a number of coping mechanisms (e.g. borrowing money,
loans and selling assets) in an attempt to offset the costs
of accessing care, which can push them into debt and
poverty [7, 21, 27–35]. These financial barriers may be
exacerbated for vulnerable population subgroups [36],
including the less-educated, the elderly, ethnic minor-
ities, farmers, migrant workers [20, 37, 38], those with
co-morbidities such as diabetes [39, 40] and as well as
varying with gender [41–45]. Such groups may be ex-
posed to greater risk of developing disease, as well as
worse treatment outcomes due to poor socioeconomic
status, access, knowledge of TB and relevant services,
lack of support and stigma [7, 11, 38, 41, 46, 47].
In this study, we explore barriers to successful care
with a focus on MDR-TB patients, a population that has
been relatively understudied to date [48]. In particular,
we investigate how certain groups may face greater chal-
lenges to accessing TB services, the added challenges for
patients with drug resistant disease, and how patients
and healthcare providers cope in Yunnan Province,
China. In particular, we pay attention to rural-urban dif-
ferences and capture perspectives of TB/MDR-TB pa-
tients and frontline healthcare providers.
Methods
Study setting: Yunnan province and its TB control system
Yunnan is China’s most south-westerly province (see
Fig. 1) with a total area of 394,100 Km2, 94% of which is
mountainous. Approximately 74% of its 46 million popu-
lation are reported to live in rural areas and, although 67%
belong to the Han ethnic group, Yunnan is one of China’s
most ethnically diverse provinces. Compared to many
other parts of the country, Yunnan has a relatively high
TB burden (a provincial TB notification rate of 60 per
100,000) and poverty rate, and there is considerable geo-
graphic variation in TB burden (with prevalence rates as
high as 1050 per 100,000 in some counties) and treatment
outcomes across the province [6, 49].
Yunnan reported full DOTS coverage in 2004 and, by
2005, reported over 70% of smear-positive cases were
being diagnosed through the DOTS programme and an
average treatment success rate of over 90% [6]. However,
substantial delays from the onset of symptoms to TB
treatment have been recorded, with one third of patients
delaying more than 90 days before seeking care at a
DOTS-implementing health centre for their TB disease
symptoms [5]. Furthermore, the cure rate was below
85% in 26 out of 129 counties in Yunnan, and non-cure
was associated with low income [6]. The public’s know-
ledge of TB prevention and control in Yunnan has been
reported as lower than national averages and that pa-
tients’ knowledge of TB was a significant factor in influ-
encing treatment outcomes [6, 50].
Similar to other provinces across China, TB control is
organised through a decentralised semi-vertical system
[3, 9, 22], with more specialist skills and knowledge, ac-
tivities and medical equipment found at higher adminis-
trative levels. All people with symptoms consistent with
TB should be referred to the county TB dispensaries,
which are affiliated with the Centre for Disease Control
(CDC) and form the primary facilities for TB diagnosis
and treatment. Yunnan’s ‘free’ TB treatment and diagno-
sis policy includes the following services: sputum smear
test, chest X-ray and anti-TB medication distributed by
the government [12]. Where other health services are re-
quired, patients may be referred as inpatients to the
Tuberculosis Control Centre (TCC) or No. 3 Hospital,
both located in Kunming.
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While TB medication and diagnosis remain free at
CDC facilities, free MDR-TB and extensively drug resist-
ant TB (XDR-TB) treatment and diagnosis have been
discontinued since June 2014 following the end of fund-
ing by The Global Fund to Fight AIDS, Tuberculosis and
Malaria (GFATM). However, patients who commenced
MDR-TB treatment before this date continue to receive
free medication, together with some of the other
GFATM funded care, which includes: free diagnosis;
contributions to transport costs; and nutritional support.
A second key difference between TB/MDR-TB treatment
for rural patients, is that the former is decentralised to
the county and village level, while the latter at the time
of the study was centralised to Kunming (see Fig. 1).
Study sampling and data collection
In-depth interviews and focus group discussions (FGD)
were conducted between August 2014 and May 2015
with TB/MDR-TB patients (with a stronger emphasis on
interviewing those diagnosed with MDR-TB where
Fig. 1 Map of Yunnan province and neighbouring countries. Map modified following terms and conditions of use (http://d-maps.com/
conditions.php?lang=en) in accordance with ‘D-Maps.com. Free maps, free blank maps, free outline maps, free base maps’ copyright permissions:
China (http://d-maps.com/carte.php?num_car=11570&lang=en) and Yunnan province (http://d-maps.com/carte.php?num_car=19490&lang=en)
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possible) and health professionals in the main TB hospi-
tals in Kunming, as well as at health centres in two rural
counties in Yunnan province. Sampling of participants
and health centres in rural Kunming followed conveni-
ence and purposive approaches, with emphasis placed
on exploring patients (Additional file 1 Annex 1) and
health professionals’ (Additional file 2 Annex 2) diverse
experiences and perceptions related to TB/MDR-TB,
taking into account: gender, age, ethnicity, prefecture of
residence, occupation, and TB/MDR-TB status. The lim-
ited number of health professionals working directly
with TB/MDR-TB patients in the region, meant that data
saturation (i.e. when novel ideas cease to emerge during
recent interviews) was reached with a smaller sample of
the former compared to the latter. Hence, FDGs were only
conducted with patients, and were deemed unnecessary to
explore health professionals accounts further.
The focus of the interviews and FGDs with patients
(Additional file 3 Annex 3) was on their experiences,
knowledge and perceptions of TB/MDR-TB, including:
diagnosis, treatment and transmission; support and as-
sistance; disclosure and impacts; and expectations for
their future. While interviews with health professionals
also covered many of these topics, they also explored
perceptions of: barriers to care and treatment; stigma
and social sanctions; roles of support networks; and lay
understandings. Interviews varied in duration between
40 min to 3 hours (an hour and half on average), while
FGDs lasted approximately one hour. The interviewer
was a male native English speaker, while the interpreter
was a female native Mandarin speaker. This allowed
flexibility in terms of gender differences during inter-
views: i.e., if the participant felt more comfortable speak-
ing to a woman they would direct their conversation to
the interpreter or a man to the researcher.
Data analysis
All in-depth interviews were conducted in Mandarin via
simultaneous translation to English by a professional in-
terpreter and digitally recorded, while the researcher
took extensive field-notes. The FGDs were conducted in
Mandarin and digitally recorded. The recordings were
directly transcribed and translated to English (literal
translation). Analysis followed a combination of open
and thematic coding, based on consultation of previous
literature and notes taken during fieldwork. Coding was
conducted on FGD transcripts and a combination of
field-notes and interview transcripts. Thus, codes were
identified based on their recurrence and wider relevance,
including those relevant to TB/MDR-TB literature. In
addition, codes and preliminary findings were shared
and discussed at three dedicated meetings with health
professionals in Kunming, which provided further
feedback on our interpretation of the data and allowed
for any necessary fine-tuning of the analysis.
Results
Overview of study participants
Twenty-one interviews were conducted with health pro-
fessionals (see Table 1); 13 of which, worked in specialist
TB/MDR-TB wards or health centres. A total of 54 (see
Table 2) patients participated, with 26 TB/MDR-TB pa-
tients (17 men and nine women) interviewed and an
additional five FGDs conducted with four to eight pa-
tients in each (a total of 19 men and nine women); al-
most half of patients were confirmed with MDR-TB (25
in total, with a further 9 not sure of their status or waiting
for confirmation). Women (44%) and men participated in
almost equal numbers (see Table 2); an intentional effect
of the purposive sample, which sought to provide a
gender-balance to participants’ accounts. However, in ac-
tuality, health staff reported a lower number of women
compared to men patients diagnosed and attending TB/
MDR-TB services, which appeared to be evident, based on
the difficulty in recruiting sufficient women into the study.
All of the interviews and FGDs were conducted in
Kunming city, except a total of eight patients and
eight healthcare professionals, who were interviewed
in their counties of residence and work-Luquan and
Yiliang (over 120 and 50 km, respectively)-both in
Kunming prefecture (see Fig. 1).
The predominance of farmers (48%) and rural patients
(64%), as well as the presence of ethnic minorities (in-
cluding Yi, Bai, Lisu, Lahu, Miao, and Zhuang) amongst
those interviewed, appeared to reflect health staff ’s
observations, that patients with some or all of these
characteristics were the most commonly and severely
affected by TB/MDR-TB, and its associated costs.
Farmers estimated their annual household incomes at
up to 50,000 Yuan (approximately 8,000 USD). Interviews
and FGDs also included: a construction contractor and
workers, a banker, photographer, university students, a
doctor, factory workers, a man who worked in human re-
sources, a shop owner, a migrant worker, and retirees. The
majority of patients came from (see Fig. 1) Yunnan prefec-
tures other than Kunming (70%), such as Zhaotong,
Diqing Tibetan Autonomous and Nujiang Lisu
Autonomous prefectures, while a few came from
Table 1 Characteristics of healthcare providers interviewed (n= 21)
Position Men Women Total
Doctor 4 6 10
Nurse 0 5 5
Outreach/Community worker 0 2 2
Management 1 3 4
Total 5 16 21
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provinces further away (i.e. Guizhou and Hunan provinces).
Patients quoted costs of travel to Kunming ranging from 10
to 900 Yuan (1–140 USD) and up to 2 days of travel, in-
cluding distances over 600 km and travelling parts of their
journey on foot.
Financial barriers and inequalities in accessing TB/MDR-TB
care
Healthcare providers and patients both described finan-
cial constraints as the most common challenge faced by
patients; hence, we have elected to focus this paper’s
analysis in relation to financial barriers. Others barriers
discussed, many of which were also linked to socio-
economic status, included: deterioration of a patient’s
health, stigma, geographical accessibility to TB services,
side effects, language, knowledge of TB and related
health services, and lack of social and emotional support.
Although most of the barriers were reported across gen-
der, age, ethnicity, prefecture of residence, educational
background and socioeconomic status, how they mani-
fested, their impact on a patient’s treatment course, and
the extent to which they were experienced varied ac-
cording to these same factors.
Financial burden in spite of “free” TB and MDR-TB
treatment and diagnosis policy
Patients and staff viewed the availability of free TB and
MDR-TB medication as central to ensuring adherence
and treatment success. The majority of TB patients re-
ported opting for the free TB medication provided at
CDC treatment centres. However, a few said they paid
for their medication at government hospitals quoting
costs varying between 50 and 250 Yuan (7–39 USD) per
month. The reasons they gave for paying for medication,
included: did not trust free medication; side effects; and
lack of awareness of its availability.
The impact of discontinuation of the GFATM funding
for MDR-TB treatment and diagnosis was identified as a
major financial challenge for all patients. Most MDR-TB
patients struggled to provide the precise costs of their
anti-MDR-TB drugs following the GFATM cuts. When
given, the cost of MDR-TB exceeded those cited for TB
medication, ranging from 400 to 10,000 Yuan (63 to
1,571 USD) per month. Even with the availability of free
TB and MDR-TB services funded by the GFATM, patients
would frequently cite paying 800–900 Yuan (125–140
USD) per month for ancillary drugs and, in some circum-
stances, were unable to differentiate between them and
the anti-TB drugs.
Costs of accessing care
Patients and staff described a disproportionate financial
burden on rural groups and ethnic minorities, with
higher total costs incurred due to longer distances trav-
elled for relevant services and the greater impact of costs
due to lower relative incomes and savings. In addition, a
number of health staff noted that in specialist TB hospi-
tals in Kunming it was not uncommon for TB tests for
rural patients to be repeated due to a lack of trust in the
reliability of tests conducted in their home counties,
which contributed to further costs and delays for pa-
tients coming from outside Kunming. Healthcare pro-
viders also observed that ethnic minorities, who spoke
their own languages and lacked fluency in Mandarin,
would frequently incur extra costs related to their TB or
MDR-TB care. This was evident in healthcare staffs’ re-
ports and from ethnic minority patients interviewed;
among the latter, all came from rural backgrounds and
almost all were accompanied by at least one other family
member, who would help care and translate for them
during medical consultations, and which resulted in in-
creased costs related to transport, accommodation and
food. This was both observed and reported to be more
common for ethnic minority women due to their relative
lack of fluency in Mandarin compared to men.
Table 2 Characteristics of patient interviewees and participants
of FGDs (total = 54)
Participant’s characteristics Women (n = 24) Men (n = 30)
Age (years)
18–30 7 10
31–45 8 6
46–60 8 12
60+ 1 2
Ethnicity
Han 17 24
Minority 7 6
Residence
Kunming Prefecture
(Yunnan Province)
8 8
Non-Kunming Prefecture
(Yunnan Province)
13 19
Non-Yunnan Province 3 3
Urban/rural residence
Urban 10 9
Rural 14 21
Occupation
Farmer 8 18
Other 16 12
TB status
TB 8 12
MDR-TB 12 13
Unknown/Waiting for drug-
resistance test result
4 5
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For MDR-TB patients, there were additional barriers
at the time of study, due to the centralisation of treat-
ment and the duration of time (24 months) needed to
complete it. All rural patients had to travel to Kunming
on a monthly basis to receive their MDR-TB medication
and any relevant care, further adding to costs of their
treatment. For example, a Yi ethnic farming woman in
her late forties, stated the following on travelling to
Kunming to get her MDR-TB treatment:
First we take a motorbike to the closest village then we
take a bus to the county capital, Chuxiong (see Fig. 1),
it’s about 130 km and takes about four hours. I have the
NRCMS, which pays about 50% […] It takes nine hours
to get here to the hospital in Kunming and it costs
about 150 Yuan (24 USD) for a single journey. We also
have to stay in a guesthouse. The travel takes a long
time and is costly. […] We have to come back every
month to get the treatment. If two people come, we
have to pay more than 100 Yuan (16 USD) each time.
So while I go, my husband is in the house looking after
the farm.
A senior female nurse working in a dedicated TB ward
in Kunming provided a second example of one farming
couple, both of whom had MDR-TB and were receiving
support from the GFATM, she said:
[…] some patients have to walk several hours to get
their daily injections, 6 months for MDR-TB, and 12
months for XDR-TB. […] And every month they have
to come back here to pick up their medication […]
All the patients interviewed reported having some form
of medical insurance and emphasised its importance in
ameliorating the costs of TB/MDR-TB care; all rural
dwelling patients and most of those whose parents were
farmers, were covered by the NRCMS. Prices reported by
patients for the insurance scheme ranged between 80 and
200 Yuan (12–31 USD) per year. Patients and healthcare
professionals recognised that medical insurance went
some way towards ameliorating the costs associated with
TB/MDR-TB care. However, in all cases, payments were
made on a reimbursement basis and hence accessing
health services still required substantial upfront out-of-
pocket payments. This meant that patients, especially
those coming from rural areas, were presented with con-
siderable financial challenges regardless of actual coverage
levels. Options for accessing healthcare were more limited
for MDR-TB patients, as medication and diagnostic
tests could only be accessed in one designated hos-
pital in Kunming; however, an additional hospital in
Kunming was added as the study finished. As such,
all MDR-TB patients from counties outside Kunming
were forced to collect their medication in Kunming at
a lower level of reimbursement.
Strategies for coping with financial barriers
Recognising that financial constraints continually emerged
as the most significant barrier to care, we analysed pa-
tients’ and health staff ’s coping strategies for mitigating
and overcoming them.
Individual and household financial resources
Patients reported using accumulated cash savings from
previous years to pay for the costs associated with treat-
ment, or selling household assets such as livestock and
crops. It was not atypical for a patient from a farming
background to report, ‘We get our money selling our pigs
and crops, and use our savings to pay for it.’ However,
especially for rural subsistence farmers, household sav-
ings based on income from selling their crops and piece-
meal work, were typically reported to be insufficient to
cover a full course of TB treatment, and even less so for
MDR-TB. A few patients reported borrowing money
from a financial institution to cover household costs, in-
cluding their care.
Direct and indirect family support
No patient stated that they were able to manage the
costs of their MDR-TB or TB infection alone. Almost all
said they relied in some capacity on their family, either
for informal cash transfers in the form of gifts or loans,
or for care giving as well as replacement labour. The
MDR-TB infected Yi woman quoted earlier, stated:
I borrowed money from sisters and my husband’s
sisters, but we still have not paid them all back yet. I
only have 4000 Yuan (628 USD) and I still have to pay
back one sister. We feel very uncomfortable. Our
daughter has given us 1000 Yuan (157 USD) […]
A patient’s inability to work due to infection with TB
or MDR-TB was frequently identified as a major burden
for subsistence farmers, who had little disposable in-
come. Under these circumstances, family members were
also drawn upon to ensure the work on their farms did
not stop. As a male farmer with TB said:
It affects our income. Once you are diagnosed with
TB, you can’t work […] In the past, while I was
healthy, my wife took care of the children, and I went
out to work. Now, my wife goes out to work, and I
stay home taking care of the children.
Drawing on multiple coping strategies
Due to the extreme financial burden, most MDR-TB pa-
tients reported relying on multiple different sources of
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funding, having exhausted one after another over the long
duration of treatment. A not uncommon example for
rural residents and farmers was provided by a 41-year-old
MDR-TB infected ethnic Lisu woman from remote
north-western Diqing Tibetan Autonomous prefecture
in Yunnan over 600 km from Kunming (see Fig. 1):
The first time I was hospitalised, we borrowed 6000
Yuan (942 USD). The second time we borrowed 5000
Yuan (785 USD). We have just paid our debts, and
then we had to sell my motorbike for 4000 Yuan (628
USD) and borrow 8000 Yuan (1256 USD). We have
borrowed money from our relatives; 1000 (157 USD)
from one, another 1000 from others. Now we have to go
back to sell the buffalos for about 4000–5000 Yuan each.
Direct and indirect support by healthcare providers
Costs of accessing care were a major burden on patients,
and could result in friction between some healthcare
staff and patients. Staff in the specialist TB hospital in
Kunming were well aware of the complexities and costs
of TB/MDR-TB care and the burdens they placed on pa-
tients coming from rural and poorer areas. Providers
and patients reported cases where providers made spe-
cial efforts to support treatment. One MDR-TB infected
man explained that his doctor had accommodated his
need for a modified self-administered care plan, while
continuing to prescribe the necessary drugs:
I live far from the clinic, about four to five kilometres
by foot; it’s very poor access. Every time I got back from
the clinic my coughing got worse. So I called the
doctors and asked whether I could take the injections
by myself, because the previous practice was very bad
for me. The doctor said it was fine on the condition
that I use the medicine subscribed by them. So I bought
saline and bags by myself, and used the drug given by
the doctor. After 1 month, my situation got a lot better.
Some healthcare providers also felt compelled to give
directly via personal donations of clothes, money, odd
jobs or surplus drugs. One nurse in her thirties working
in Kunming noted:
Some people don’t even have enough money for food.
One man came with his wife who helped to look after
him. They had only one bun for each meal and one
meal a day. So we gave them some money and free milk
to help them […] when we gave them some medication
we used stuff that hadn’t been completely finished (for
example, when injections are done by weight).
In another case, a female nurse, who was largely re-
sponsible for counselling TB patients and their families,
recounted how the providers at the TB hospital not only
donated cash, but found ways to provide employment
for the patients and their family members:
The mother and two sons have MDR-TB, so only the
father could work to get money in Qujing prefecture
(approximately 150 km east of Kunming; see Fig. 1),
so for example, we thought of having her son as a
peer educator and the father as doing some jobs in
the clinic.
Impact on patients and healthcare providers
In spite of the presence of free or subsidised care, insur-
ance and the supporting strategies adopted above, most
patients and staff viewed TB/MDR-TB as having a cata-
strophic impact on household finances.
Impoverishment
According to many healthcare providers and patients, it
was not uncommon for patients to face impoverishment
and the exhaustion of all financial reserves. This was de-
scribed by a female farmer in her fifties with MDR-TB,
from a county outside Kunming city (approximately 120
km.), when describing the situation of her MDR-TB in-
fected husband:
Because he has diabetes, it has pushed up the costs a
huge amount! Also he is unable to work, so the
financial costs are very hard; treating TB and diabetes
at the same time. We have had to borrow money
from relatives. In recent years we have spent tens of
thousands of Yuan. We have no savings left, we have
used them all up!
At the same time, patients reported that the financial
consequences resulted in reduced consumption or com-
promises in medication in ways that might adversely im-
pact treatment success. In the case of the MDR-TB
couple who were previously described as eating only one
meal per day, another nurse described how the house-
hold still could not prevent bankruptcy, even while redu-
cing consumption to near-starvation levels:
They live in a county that belongs to Kunming, in a
very remote village that takes 2 days to get here. Only
his check-ups and MDR-TB medication are covered
by the GFATM, but not the transport or food. He has
been on and off treatment for over 10 years. He even
went bankrupt.
Strained relationships and social stigma
Reliance on family or community members for support
led in a number of cases to the erosion of social
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standing, strained relationships and social stigma. On a
few occasions support was accompanied by serious
questions as to the value of pursuing a course of medica-
tion and all the associated costs, when there was no
guarantee whether they would be cured or not. This was
particularly true for MDR-TB patients whose known
length of infection and course of treatment was consid-
erably longer than those with TB.
Patients often reported experiencing strong guilt
and shame (as being a ‘burden’) when discussing the
support, which they received from family members,
relatives and friends. In addition to its physical toll,
TB infection (and MDR-TB especially) eroded social
capital, including affecting traditional gender and
generational roles within a family, leading to social
stigma and considerable pressure on their psycho-
logical well-being. This was noted by various MDR-
TB patients, such as the two male farmers quoted
below:
I feel indebted to my family, especially the children, I
feel pressured. Because I am a farmer, I don’t have
much income, now I have no income and feel guilty
for my family. I have three children, the eldest one is
in grade one of junior high school, another one is in
grade five of primary school. They are all in school,
we are short of money.
I feel so sad. I am sick and unable to help my family.
Seeing my parents working, I feel so uncomfortable.
For many of the male patients, this manifested as a
result of the disruption of their traditional role as a
‘bread earner’ and meant their wives, parents or other
family members would potentially have to take on
this role, leaving some men to taken on their wife’s
role as a carer for their children. In another, perhaps
extreme, case, an elderly woman with MDR-TB said
that after borrowing money a number of times from
her sisters for treatment, they had cut ties with her
after they had repeatedly referred to her as useless
and that she was better off dying, with which she
herself agreed with:
They say “we hope you die.” They think I am a waste
of money. […] So when my sisters complain about it, I
respond, “I will just wait till my daughter is married. I
don’t want to live or be treated after that.”
From a provider perspective, staff were well aware that
helping patients beyond their remit was of limited use
and that more systemic solutions would have to be
found. As a nurse working in a TB designated centre in
Kunming explained:
Staff also donated money in the past, but this is not
sustainable. So we have to rely on government policy
to help these people.
Discussion
This paper explores experiences and opinions of health-
care providers and patients in Yunnan province, China,
focusing on financial-related barriers and inequalities in
the provision of, and access to, MDR-TB/TB care. Unlike
other studies on this topic, we also investigated coping
strategies and their impacts on patients and households,
which potentially require the support of policy makers.
Our study indicates that financial constraints were
identified as the most pervasive barrier to care amongst
patients and health care professionals. Barriers appeared
to be magnified for ethnic minorities and patients com-
ing from rural areas [7], especially for farmers and those
infected with MDR-TB. Cuts in the GFATM financing
resulted in the withdrawal of previously subsidised ser-
vice, and costs of extra diagnostic tests, drugs for side-
effects and travel, accumulate during the long course of
treatment. Typical coping strategies documented in
other studies [7, 10, 21, 28, 29, 33] – such as selling their
crops and household assets, taking out loans and relying
on family members to provide financial and non-
financial support-were also represented. We also found
that healthcare providers empathised with MDR-TB pa-
tients and understood the magnitude of the challenges
they face, trying to help beyond their medical care remit
where possible, by voluntarily and spontaneously con-
tributing financial and non-financial aid. Our findings
indicate that these coping measures were frequently in-
adequate from the perspective of both patients and pro-
viders [30]. Patients and families were unable to avert
poverty and the total-and potentially catastrophic-costs
of accessing care, while experiencing a significant social
emotional and psychological toll, for some in the form
of strained familial relationships and social stigma.
Furthermore, front-line providers were limited in their
capacity to provide coping strategies that could cover
shortfalls in patients’ finances through unorthodox
means.
This study provides further insights into factors driv-
ing the higher TB burden and slower declines in preva-
lence in rural compared to urban areas in China [24].
Rural patients appear to face lower availability and qual-
ity of care, but higher absolute as well as relative costs
due to the need to travel and lower incomes, respect-
ively, and have been shown to be more likely resort to
coping strategies compared to urban populations and
suffer catastrophic costs [27, 33]. This is compounded
by the fact that socioeconomic advantages, such as ac-
cess to jobs and educational opportunities, quality of
roads and availability of frequent public transport, all
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favour urban residents [51]. In the case of MDR-TB
treatment, rural-urban inequities were particularly se-
vere as medication, specialist medical knowledge and
equipment are limited to urban locations (the provincial
capital, Kunming), but were not available at county hos-
pitals or village clinics. Although less pronounced in the
case of TB treatment, these inequities also perpetuate a
disproportionate risk of developing MDR-TB in the fu-
ture [52, 53].
From a policy perspective, our work confirms that
China’s subsidised TB and-previously subsidised -
MDR-TB treatment are perceived to be necessary, but
insufficient for ensuring continued access to relevant
care for patients [10–12, 16]. Similarly, the New Rural
Cooperative Medical Scheme provides crucial, but in-
sufficient coverage of treatment for many patients
[14, 27, 54, 55]. Thus, our findings are consistent
with previous work suggesting that vulnerable popula-
tions, such as rural residents have benefitted least
from China’s economic development and health sys-
tem reforms over the last 30 years and that current
measures are insufficient to provide financial protec-
tion from the potentially catastrophic costs of TB/
MDR care, especially for low income groups [56, 57].
A recent attempt to make MDR-TB more affordable
for patients in China by limiting patients out-of-
pocket spending to 10% was still found to be insuffi-
cient [58]. Together with this study and others [21,
27, 32, 59], we suggest a need for greater attention to
the total direct and indirect costs to individuals and
society.
Differential financial support and targeted investment
for vulnerable groups, especially for those coming from
rural areas, which takes into account indirect costs (i.e.
transport, loss of work, language barriers and home
care) will be essential to financially protect patients and
households and improve health outcomes. The following
measures might go some way to resolving the total costs
faced by some TB/MDR-TB patients: increased insur-
ance reimbursements and subsides for MDR-TB pa-
tients; formal prepayments schemes and multi-sectoral
social protection networks for households, with invest-
ment beyond the health sector; geographically targeted
investment and development to reduce inequities in ac-
cess to equivalent financial and health services, such as
community DOTs; and where possible, decentralisation
of quality TB/MDR-TB services [5, 29, 31, 32, 60–62].
The successful selection and implementation of such
policies and interventions could benefit from supple-
mentary quantitative research, which documents the
magnitude and central determinants of patient costs, in-
cluding, demographically disaggregated data on indirect
costs, economic contributions of patient coping strat-
egies and costs of care relative to household incomes
[21, 27, 33]. This would not only ensure better outcomes
for cost mitigation and reduction of financial barriers for
patients access to care, but also treatment adherence
and monitoring of progress to the End TB strategy
target of zero catastrophic costs [63]. In addition, fur-
ther qualitative exploration of the social impacts (i.e.
impoverishment, strained relationships and social
stigma) of costs associated with TB/MDR-TB care
would strengthen the development and implementa-
tion of any interventions based on quantitative find-
ings through providing relevant contextual data to
improve delivery and targeting.
The main limitation of our study is its sample size
and restricted geographical focus to the provincial cap-
ital city of Kunming, two surrounding counties and
public health facilities; largely, a practical question of
time and costs to conduct the research. Attempts were
made to overcome these issues by interviewing patients
from rural settings that had arrived at the (urban) spe-
cialist health centres; this provided insights into those
who have succeeded, to varying degrees, in accessing
services in Kunming despite potential barriers, and pro-
vides important insights into the factors necessary for
other patients to do so. However, the experiences of pa-
tients that were not able to, or chose not to come to
Kunming were not captured. This means that the study
should not be taken as representative of Yunnan as
whole. Rather, the experiences and opinions of those
interviewed has enabled the identification of areas of
potential concern for policy and future research.
Conclusion
Our study shows that barriers to care and adverse
impacts of disease may be exacerbated for rural pa-
tients, and especially those infected with MDR-TB, as
critical health services (including, medication and
diagnostic tests) are concentrated in major cities and
costs of care can be catastrophic for some house-
holds. Geographical and socioeconomic differences
not only contribute to the unequal burden of MDR-
TB (and TB) costs, but may also potentially affect its
development and spread. Coping mechanisms-such as
patients’ reliance on family members and healthcare
workers provision of personal contributions to the
poorest individuals-are helpful, but often unsustain-
able and insufficient, raising new challenges. To re-
duce financial barriers, improve treatment outcomes
and minimise catastrophic health costs, there is a
need for further research into the total direct and in-
direct costs of accessing TB/MDR-TB care and their
social consequences. This will enable better assess-
ment and targeting of appropriate financial support
for identified vulnerable groups and geographic devel-
opment of TB/MDR-TB services.
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